Bristol Myers Squibb Shares Purchased by Krilogy Financial

Institutional investor boosts stake in pharmaceutical company

Apr. 20, 2026 at 10:14am

Got story updates? Submit your updates here. ›

An extreme close-up of shiny, interlocking metal gears and machinery, representing the complex financial infrastructure and institutional investment supporting the pharmaceutical industry.Institutional investors continue to back Bristol Myers Squibb's pharmaceutical business, signaling confidence in the company's long-term growth prospects.Princeton Today

Krilogy Financial LLC, an institutional investor, increased its position in Bristol Myers Squibb Company (NYSE:BMY) by 61.7% in the fourth quarter, according to a recent SEC filing. The firm now owns 73,468 shares of the biopharmaceutical company's stock, valued at $4,011,000.

Why it matters

This transaction indicates growing institutional confidence in Bristol Myers Squibb, a major pharmaceutical company focused on cancer, immunology, and other therapeutic areas. The stock purchase suggests Krilogy Financial sees potential upside in BMY shares.

The details

Krilogy Financial acquired an additional 28,033 shares of Bristol Myers Squibb in the fourth quarter, bringing its total position to 73,468 shares. Other institutional investors have also made changes to their BMY holdings, with some increasing and others decreasing their stakes in the company.

  • Krilogy Financial reported the share purchase in a Q4 2025 SEC filing.

The players

Krilogy Financial LLC

An institutional investor that manages assets for clients.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Krilogy Financial in Bristol Myers Squibb suggests Wall Street sees growth potential in the pharmaceutical company's pipeline and business outlook, even as the stock has generally traded in a range in recent quarters.